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Abstract. Vascular endothelial growth factor (VEGF) 
produced from tumor cells plays a crucial role in the patho-
genesis and neovascularization of neuroblastoma. Inhibition 
of VEGF secretion by tumor cells, as well as VEGF-regulated 
signaling in endothelial cells, are important to reduce the 
angiogenesis and growth of neuroblastoma. Since melatonin 
has anti-angiogenic effects in tumor cell lines, the aim of 
the present study was to study melatonin modulation of the 
pro-angiogenic effects of VEGF in neuroblastoma cells 
(SH-SY5Y). We used co-cultures of SH-SY5Y and endothelial 
cells. VEGF expression and protein levels were analyzed by 
quantitative RT-PCR and ELISA, respectively. Endothelial 
cell migration was assessed by wound-healing assay and 
endothelial angiogenesis by a tube formation assay. Melatonin 
inhibited the pro-angiogenic effects of SH-SY5Y cells. The 
conditioned medium collected from the neuroblastoma cells 
was angiogenically active and stimulated proliferation, migra-
tion and tube formation in endothelial cells. This effect was 
significantly counteracted by the addition of either anti-VEGF 
or melatonin. Melatonin inhibited VEGF expression and 
secretion in SH-SY5Y cells, decreasing the levels of VEGF 
available for endothelial cells. Melatonin has anti-angiogenic 
effects at different steps of the angiogenic process in SH-SY5Y 
neuroblastoma cells, through the downregulation of VEGF.
Introduction
Angiogenesis is the process of the development of the 
intrinsic vascular network, and it is an essential event in the 
progression and metastatic spread of solid tumors such as 
neuroblastoma, where new capillaries spread from preexisting 
vessels and the transition from avascular to vascular phase 
occurs via neovascularization (1). Angiogenesis is mediated 
by multiple regulatory factors such as growth factors, adhesion 
molecules and matrix degrading enzymes. The balance 
between angiogenic activators and inhibitors maintains 
endothelial cells in an angiogenic or quiescent stage (2). 
Malignant neuroblastoma is a highly vascularized solid tumor 
that requires access to blood vessels for growth, invasion 
and metastasis, being highly dependent on angiogenesis (1). 
Therefore, anti-angiogenic strategies can be effective in 
inhibiting tumor cell dissemination and metastasis in highly 
vascular neuroblastoma (3,4). Vascular endothelial growth 
factor (VEGF) is the most active endogenous pro-angiogenic 
factor, and it can induce angiogenesis by directly acting on the 
endothelium in vivo as well as by increasing the microvascular 
permeability (5). VEGF is widely known to play an important 
role in tumor biology and more specifically, in the process of 
tumor angiogenesis, as VEGF expression plays a crucial role in 
the pathogenesis and neovascularization of neuroblastoma (1). 
VEGF signaling plays a regulatory role in neuroblastoma 
angiogenesis via a paracrine mechanism through two specific 
tyrosine kinase VEGF receptors, VEGFR-1 and VEGFR-2, 
located at the surface of endothelial cells. Tumor-induced 
VEGF secretion may function in both paracrine and autocrine 
manners to allow tumor expansion and growth (6). Treatment 
of neuroblastoma in both in vitro and in vivo models with an 
anti-VEGF agent results in antitumor activity with a decrease 
in both tumor vascularity and in the number of intratumoral 
vessels and a decrease in VEGF expression suggesting a 
diversified role of VEGF in the progression of advanced stage 
neuroblastoma (7,8).
Melatonin, the main secretory product of the pineal gland, 
is widely known to decrease the growth and development of 
estrogen-responsive breast cancers (9-12). Melatonin exerts 
its oncostatic properties in hormone-dependent breast cancer 
by interfering at different levels with the estrogen signaling 
pathways (13-15). Melatonin downregulates circulating 
levels of gonadal estrogens, interferes with the activation 
of the estrogen receptor and regulates the activity and 
expression of several enzymes involved in the biosynthesis 
of estrogens in tumoral and peritumoral tissues (16-19). 
In vitro studies demonstrated that melatonin plays a role in 
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the paracrine interactions between malignant epithelial and 
proximal endothelial cells, through the downregulation of 
VEGF expression in human breast cancer cells, decreasing 
the levels of VEGF around endothelial cells and decreasing 
angiogenesis. VEGF secreted by breast cancer cells interacts 
with VEGF receptors in endothelial cells and stimulates 
downstream signaling molecules to promote proliferation, 
growth, survival and migration of endothelial cells (20-22). 
Therefore, inhibition of VEGF secretion by tumor cells, as 
well as VEGF-regulated signaling in endothelial cells, could 
be important in decreasing tumor angiogenesis and growth.
Since melatonin has anti-angiogenic effects in other 
tumor cell lines (23), in the present study, we investigated 
the anti-angiogenic activity of melatonin at different steps 
of the angiogenic process in SH-SY5Y neuroblastoma cells. 
We studied whether melatonin decreases the pro-angiogenic 
effects of VEGF, as well as the conditioned media from 
SH-SY5Y neuroblastoma cells. To accomplish this, we used 
cultures of neuroblastoma cells (SH-SY5Y) and co-cultures of 
SH-SY5Y cells with human umbilical vein endothelial cells 
(HuVECs).
Materials and methods
Cells and culture conditions. HuVECs were purchased from 
the American Type Culture Collection (ATCC; Rockville, 
Md, uSA). They were maintained as monolayer cultures in 
75 cm2 plastic culture flasks containing Vascular Cell Basal 
Medium (VCBM) supplemented with endothelial cell growth 
kit-BBE (both from ATCC) which consisted of 2% fetal bovine 
serum (FBS) (PAA Laboratories, Pasching, Austria), 0.2% 
bovine brain extract, 5 ng/ml rhEGF, 10 mM L-glutamine, 
0.75 u/ml heparin sulfate, 1 µg/ml hydrocortisone hemisuc-
cinate, 50 µg/ml ascorbic acid, penicillin (20 u/ml) and 
streptomycin (20 µg/ml) (Sigma-Aldrich, Madrid, Spain), at 
37̊C in a humid atmosphere containing 5% CO2. To avoid 
genetic mutation and low viability, no more than 6 passages of 
HuVECs were used for the experiments.
SH-SY5Y neuroblastoma cells were a kind gift from 
dr María Elsa Valdizán, from the Pharmacology division 
of the department of Physiology and Pharmacology of the 
university of Cantabria (Spain). They were maintained as 
monolayer cultures in 75 cm2 plastic culture flasks in Dulbecco's 
modified Eagle's medium (DMEM)/Ham's Nutrient Mixture 
F-12 (Sigma-Aldrich), supplemented with 10% FBS, penicillin 
(20 U/ml) and streptomycin (20 µg/ml) at 37̊C in a humid 
atmosphere containing 5% CO2.
Conditioned media collection for experimentation. SH-SY5Y 
cells were seeded into 24-multiwell plates (25x104 cells/well) 
in DMEM/Ham's Nutrient Mixture F-12 supplemented with 
10% FBS and incubated at 37̊C. When a homogenous mono-
layer of pre-confluent SH-SY5Y cells was reached (48 h), the 
cells were washed twice with PBS and placed in serum-free 
VCBM. After 24 h of incubation, the conditioned medium was 
collected, filtered through a 0.2-µm pore size membrane to 
remove particles and stored at -80̊C.
Cell proliferation assay. SH-SY5Y were seeded into 
96-multiwell plates at a density of 25x103 cells/well in 
DMEM/Ham's Nutrient Mixture F-12 supplemented with 
2% FBS and incubated at 37̊C. After 24 h of incubation, 
the media were aspirated and replaced by fresh media 
supplemented with 5% charcoal-stripped FBS (sFBS) 
containing either 1 mM or 1 nM melatonin (Sigma-Aldrich) 
or vehicle (ethanol at a final concentration of <0.0001%). Cells 
were cultured for 6 days and proliferation was assessed using 
the [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium 
bromide] (MTT) method (24), with a reading absorbance at 
570 nm on a microplate reader (Labsystems Multiskan RC 351; 
Vienna, VA, uSA). MTT was obtained from Molecular Probes, 
Inc. (Eugene, OR, uSA).
Paracrine effects of SH-SY5Y conditioned medium on 
endothelial cell proliferation. HuVECs were seeded at 
8x103 cells/well in a 96-well multiplate containing VCBM 
supplemented with 2% FBS overnight. Cells were washed 
twice with PBS and the media were replaced with serum-free 
VCBM containing SH-SY5Y conditioned media alone or 
supplemented with 1 mM melatonin or 150 ng/ml anti-VEGF 
(R&d Systems Europe Ltd., Abingdon, uK). The cells were 
then cultured for 24 h and cellular proliferation was assessed 
using the MTT method.
Co-culture of HUVECs and SH-SY5Y cells. HuVECs were 
co-cultured along with SH-SY5Y cells using Falcon 24-multi-
well plates and Falcon cell culture inserts. HuVECs were 
plated (24x103 cells/well) on the bottom wells containing 
VCBM supplemented with 2% FBS and incubated overnight. 
Subsequently, SH-SY5Y cells were seeded (35x103 cells) on 
the permeable membrane (0.45-µm) of the tissue-culture 
inserts containing VCBM supplemented with 2% FBS for 24 h. 
The media were then changed to serum-free VCBM for 72 h 
containing melatonin (1 mM) or vehicle (ethanol). At the end 
of the experiment, the media were collected, centrifuged to 
remove particles and subjected to the assessment of the protein 
levels of VEGF. Cells in the bottom plate were evaluated for 
proliferative indices by MTT method.
Assessment of VEGF mRNA expression. Analysis of the VEGF 
expression in SH-SY5Y cells was carried out by RT-PCR after 
incubation of cells with either 1 mM, 1 µM and 1 nM of mela-
tonin and/or 100 µM CoCl2 (Sigma-Aldrich) and/or vehicle 
(ethanol) for 4 h. Total RNA was isolated from SH-SY5Y cells 
and purified with the Nucleospin RNA II kit (Machenery-Nagel, 
Düren, Germany) following the manufacturer's instructions. 
The absorbance ratio A260 nm/A280 nm was >1.8. For cdNA 
synthesis 0.5 µg of total RNA was denatured at 65̊C for 10 min 
and reverse-transcribed for 50 min at 45̊C with a cDNA 
Synthesis kit (BioLine, London, UK) in a final volume of 20 µl 
in the presence of 500 ng of oligo(dT) (12-18 primers). 
Quantitative real-time (qRT-PCR) was performed using the 
following set of human VEGF 165 specific primers: [5'-ACCA 
AGGCCAGCACATAGG-3' (forward) and 5'-ACGCTCCAGG 
ACTTATACCG-3' (reverse)] (Sigma Genosys Ltd., Cambridge, 
UK). As a quantification control, s14 mRNA was also subjected 
to qRT-PCR using a set of specific primers: [5'-TCCTGCGAG 
TGCTGTCAGAG-3' (forward) and 5'-TCACCGCCCTACAC 
ATCAAA-3' (reverse)] (Sigma Genosys Ltd.). qRT-PCRs were 
performed on an MX3005P system (Stratagene, La Jolla, CA, 
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uSA) using Brilliant® SYBR®-Green PCR Master Mix (Applied 
Biosystems, Madrid, Spain) following the manufacturer's 
instructions. Amplifications were performed for 40 cycles using 
the following temperature profile: 60̊C, 45 sec (annealing); 
72̊C, 30 sec (extension) and 95̊C, 30 sec (denaturation).
Assessment of the protein levels of VEGF. For the determina-
tion of the concentration of VEGF in the SH-SY5Y cell cultures 
and the HuVEC/SH-SY5Y cell co-culture media, a Human 
VEGF Immunoassay kit (R&d Systems Europe Ltd.) was 
used. The samples (in triplicate) were processed according to 
the manufacturer's instructions. Briefly, SH-SY5Y cells were 
seeded into 96-multiwell plates at a density of 8x103 cells/well 
in DMEM/Ham's Nutrient Mixture F-12 supplemented with 
10% FBS and incubated at 37̊C for 24 h. Next, the media 
were aspirated and replaced by fresh media supplemented 
with 0.5% sFBS and containing either 1 mM or 1 nM of 
melatonin or vehicle (ethanol). After 24 h of incubation, the 
media were collected, centrifuged to remove particles and 
subjected to ELISA according to the manufacturer's instruc-
tions. For the determination of the protein levels of VEGF in 
the cell co-culture media, samples were collected, centrifuged 
and immediately processed. At the end of the procedure, the 
absorbance was determined at a wavelength of 450 nm, with 
the correction wavelength set at 570 nm.
Endothelial cell migration assay: Wound healing assay. 
HuVECs were seeded onto 6-multiwell plates (Falcon) 
containing VCBM supplemented with 2% FBS and were 
allowed to reach full confluency. A line of HUVECs was then 
scraped away in each plate using a pipette tip. Subsequently, 
the cells were washed twice with PBS to remove detached 
cells and SH-SY5Y conditioned media alone or supplemented 
with 1 mM melatonin or 150 ng/ml anti-VEGF were added to 
each plate. Thereafter, three randomly selected views along 
the scraped line in each plate were photographed using an 
ORCA-R2 camera (Hamamatsu Photonics, Massy Cedex, 
France) attached to a Nikon Eclipse-Ti microscope set 
(Werfen Group, Barcelona, Spain) at a magnification of x10. 
Photomicrographs, with an exposure time of 5 msec, were 
captured every 10 min during the course of the experiment, 
which was terminated as soon as the wound was completely 
filled in the vehicle-treated controls (after 8 h). Initial and final 
wound sizes were determined using the NIS-Elements v.3.8 
software (Nikon, Tokyo, Japan), and the difference between 
the two wound sizes was used to determine the migratory 
distance using the following formula: Initial wound size minus 
final wound size divided by two. Three independent experi-
ments were carried out.
Endothelial cell differentiation assay: Endothelial cell 
capillary-like tube formation assay. To study the effects of 
SH-SY5Y conditioned media on the formation of tubular struc-
tures in HuVECs we used the In vitro Angiogenesis Assay 
Tube Formation kit (Cultrex; Trevigen Inc., Gaithersburg, 
MD, USA) according to the manufacturer's instructions. First, 
reduced growth factor basement membrane extract (BME) 
was pippetted into a 24-well plate and polymerized for 1 h 
at 37̊C. HUVECs (1x105/well) were then seeded in VCBM 
supplemented with 2% FBS containing SH-SY5Y conditioned 
media alone or supplemented with 150 ng/ml anti-VEGF or 
melatonin 1 mM. After 5 h of incubation, 4 random fields were 
selected/well and tubular structures were photographed using 
a Nikon Sight dS-SML1 camera (Sendai Nikon Corporation, 
Miyagi, Japan) attached to a Nikon Eclipse Ti-S fluorescence 
microscope at a magnification of x10. The formation of the 
tubular network was assessed using ImageJ 1.45S software. 
Each assay was performed three times.
Statistical analysis. The data are expressed as the mean ± stan-
dard errors of the mean (SEM). Statistical differences between 
groups were analyzed using one way analysis of variance 
(ANOVA), followed by the Student-Newman-Keuls test. 
Results were considered as statistically significant at p<0.05.
Results
Effects of melatonin on SH-SY5Y neuroblastoma cell prolif-
eration. To investigate the influence of melatonin on the 
proliferation of SH-SY5Y cells we studied the effects of physi-
ological (1 nM) and pharmacological (1 mM) concentrations 
of melatonin on the proliferation of neuroblastoma cells. Only 
pharmacological concentrations of melatonin (1 mM) had a 
significant inhibitory effect on cell proliferation (Fig. 1A).
Effects of melatonin on secretion and VEGF mRNA expres-
sion in SH-SY5Y cells. First, we studied the effect of melatonin 
on VEGF synthesis by SH-SY5Y cells. For this purpose, we 
assessed the VEGF concentration in the SH-SY5Y-cell culture 
media. The levels of VEGF were significantly (p<0.001) 
decreased by the addition of melatonin at a 1 mM concentra-
tion (Fig. 1B).
With the aim of determining whether this inhibitory effect 
of melatonin on VEGF production was due to a downregula-
tion of VEGF mRNA expression, we incubated SH-SY5Y cells 
with melatonin (1 mM, 1 µM and 1 nM) or vehicle for 4 h, 
and total RNA was isolated to perform RT-PCR with specific 
primers for human VEGF, using s14 as a control housekeeping 
gene. Melatonin at different concentrations decreased VEGF 
mRNA expression (Fig. 2A). To mimick hypoxia, a well-
known inducer of VEGF mRNA expression, SH-SY5Y cells 
were exposed to 100 µM CoCl2 and the addition of melatonin 
at the pharmacological (1 mM) concentration, significantly 
counteracted the stimulatory effect of CoCl2 on VEGF mRNA 
gene expression (p<0.001) (Fig. 2B).
We developed co-cultures of HuVECs and SH-SY5Y cells 
to first investigate whether the presence of neuroblastoma 
cells in the cultures affects the growth of the endothelial cells. 
undoubtedly, we observed that the presence of SH-SY5Y 
cells in the co-cultures promoted an increase in HuVEC 
proliferation (p<0.001) and 1 mM melatonin counteracted this 
stimulatory effect (Fig. 3A). To study whether the increase in 
HuVEC proliferation could be due to the release of VEGF by 
SH-SY5Y cells, the co-culture media were subjected to ELISA 
to determine VEGF protein levels. The presence of SH-SY5Y 
cells significantly increased the protein levels of VEGF in the 
cell co-culture media (p<0.001) whereas the addition of 1 mM 
melatonin decreased the concentration levels of VEGF and 
counteracted the stimulatory effect induced by the presence of 
tumoral cells (p<0.05) (Fig. 3B).
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Effects of melatonin on the paracrine activity of VEGF 
produced by SH-SY5Y cells on HUVEC proliferation. To 
demonstrate that VEGF produced by tumor cells is angio-
genically active and stimulates endothelial cell proliferation, 
serum-free conditioned media from SH-SY5Y cells were 
collected and subsequently added to HuVECs to assess their 
proliferative response. When the conditioned media from the 
SH-SY5Y cells were added to the cultures, HuVEC growth 
was markedly stimulated (p<0.001) and this effect was signifi-
cantly (p<0.001) counteracted by the addition of either the 
anti-VEGF antibody (150 ng/ml) or 1 mM melatonin (Fig. 4).
Effects of melatonin on endothelial cell migration. Since 
endothelial cell migration is essential for the formation of 
new blood vessels during neo-angiogenesis, we next studied 
the effects of melatonin treatment on the migratory properties 
of endothelial cells using wound-healing assays. We studied 
whether VEGF contained in the conditioned media collected 
Figure 3. HuVECs were plated (24x103 cells/well) on the bottom wells 
containing VCBM supplemented with 2% FBS and incubated overnight. 
Then, SH-SY5Y cells were seeded (35x103 cells) on the permeable mem-
brane (0.45 µm) of tissue-culture inserts containing VCBM supplemented 
with 2% FBS for 24 h. The media were then changed to serum-free VCBM 
for 72 h containing melatonin (1 mM) or vehicle (ethanol). At the end of 
the experiment, cells in the bottom plate were evaluated for proliferative 
indices using the MTT method and the media were collected, centrifuged 
and subjected to assessment of the protein levels of VEGF. (A) The effects 
of melatonin (1 mM) on HuVEC proliferation, in the presence of SH-SY5Y 
cells in the culture. data are expressed as the percentage of the control 
group, cultures containing only HuVECs (mean ± SEM). (B) The effects 
of melatonin (1 mM) on the protein levels of VEGF in the co-culture of 
HuVECs and SH-SY5Y cells. data are expressed as the percentage of the 
control group, cultures containing only HuVECs (mean ± SEM); ap<0.001 
vs. the HuVECs; bp<0.001 vs. the HUVECs + SH-SY5Y; cp<0.05 vs. the 
HUVECs + SH-SY5Y. HUVECs, human umbilical vein endothelial cells; 
VEGF, vascular endothelial growth factor.
Figure 1. (A) Effects of melatonin (1 mM and 1 nM) or its diluent (ethanol 
at a 0.001% final concentration) on SH-SY5Y neuroblastoma cell prolifera-
tion assessed using the MTT method. (B) Effects of melatonin (1 mM and 
1 nM), or its diluent on the protein levels of VEGF in the cell culture media 
of SH-SY5Y cells as determined by ELISA. data are expressed as the per-
centage of the control group (mean ± SEM); ap<0.001 vs. the other groups. 
VEGF, vascular endothelial growth factor.
Figure 2. Effects of melatonin on VEGF mRNA expression in SH-SY5Y 
cells. (A) Cells were incubated with melatonin (1 mM, 1 µM and 1 nM) or 
ethanol (control) for 4 h. Total mRNA was isolated from cells and 
reverse-transcribed. The cDNA was subjected to PCR using specific primers 
for VEGF or s14. (B) Cells were incubated with melatonin (1 mM) and/or 
100 µM of CoCl2 or ethanol (control) for 4 h. data are expressed as the 
percentage of the control group (mean ± SEM); ap<0.001 vs. the control; 
bp<0.001 vs. the CoCl2. VEGF, vascular endothelial growth factor.
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from the SH-SY5Y cells was angiogenically active and able 
to increase the migration of HuVECs and whether melatonin 
was able to counteract this effect. Clearly, when conditioned 
media from the SH-SY5Y cells were added to the cultures the 
migration of HUVECs was markedly stimulated (p<0.001) 
and this effect was significantly counteracted by the addition 
of either anti-VEGF (150 ng/ml) or melatonin 1 mM (Fig. 5).
Effects of melatonin on HUVEC capillary structure forma-
tion. To study the effects of melatonin on the formation of 
tubular structures by endothelial cells, forming a complex 
network of vessels and capillaries, we used an in vitro angio-
genesis tube formation assay where we assessed: i) whether 
VEGF contained in the conditioned media collected from the 
SH-SY5Y cells was angiogenically active and able to increase 
the tube formation of HuVECs; and ii) whether melatonin was 
able to counteract this effect. As shown in Fig. 6, HuVECs 
plated on reduced growth factor-BME, formed a massive 
network of tubes after 5 h. When the conditioned media from 
the SH-SY5Y cells were added to the cultures, tube forma-
tion was markedly stimulated and this effect was significantly 
(p<0.001) counteracted by the addition of either the anti-VEGF 
antibody (150 ng/ml) or melatonin 1 mM (Fig. 6).
Figure 4. Effects of melatonin on the paracrine activity of VEGF produced by 
SH-SY5Y cells on HuVEC proliferation. HuVECs were cultured in 96-well 
multiplates containing VCBM supplemented with 2% FBS overnight. Cells 
were then washed twice with PBS and the media were changed to serum-free 
VCBM containing the conditioned media from the SH-SY5Y cells sup-
plemented with 150 ng/ml of the anti-human VEGF antibody or 1 mM of 
melatonin. The cells were cultured for 24 h and cellular proliferation was 
assessed using the MTT method. data are expressed as the percentage of the 
control group, cultures containing only HuVECs (mean ± SEM); ap<0.001 
vs. the control; bp<0.001 vs. the conditioned media; cp<0.001 vs. the con-
ditioned media + anti-VEGF. HUVECs, human umbilical vein endothelial 
cells; VEGF, vascular endothelial growth factor.
Figure 5. Effects of melatonin (1 mM) and anti-VEGF (150 ng/ml) on endothe-
lial cell migration induced by the CM collected from the SH-SY5Y cells and 
analyzed with the wound healing assay. Representative photomicrographs 
after 6.5 h of experimentation are shown at a magnification of x10 and the 
migratory-distance was measured as detailed in the Materials and methods. 
The migratory distance data shown are expressed as the mean ± SEM of 
three experiments; ap<0.001 vs. the control; bp<0.001 vs. the CM; cp<0.001 
vs. the CM + melatonin 1 mM. HUVECs, human umbilical vein endothelial 
cells; CM, conditioned media.
Figure 6. Effects of melatonin on the tube formation of HuVECs induced by 
the CM collected from the SH-SY5Y cells. HuVECs were seeded in medium 
with 2% FBS containing either SH-SY5Y conditioned media alone or supple-
mented with 150 ng/ml anti-VEGF or 1 mM melatonin. After 5 h, the tubular 
structures were photographed and tubule formation was asessed as described 
in the Materials and methods. Tubular-formation data are expressed as the 
percentage of the control group (mean ± SEM); ap<0.01 vs. the control; 
bp<0.001 vs. the CM; cp<0.001 vs. the CM + melatonin 1 mM. HUVECs, 
human umbilical vein endothelial cells; CM, conditioned media.
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Discussion
Neuroblastoma is the most common pediatric extracranial and 
heterogeneous solid tumor in children. It is a highly vascular 
and aggressive tumor that originates from the neural crest. 
Angiogenesis, genetic abnormalities and oncogene amplifica-
tion are mainly responsible for the malignant phenotype of 
this tumor (1). New blood vessel formation, which supplies 
vital nutrients to the growing tumor, is regulated by different 
growth factors, and VEGF is one of the most effective. VEGF 
is a critical mitogen that regulates growth, neovascularization 
and migration of endothelial cells in addition, it is expressed 
and secreted by many neuroblastoma cell lines and primary 
tumors that contribute to the growth of endothelium in vitro 
and angiogenesis in vivo leading to poor prognosis in high-risk 
neuroblastoma (1,25). SH-SY5Y is a human cell line, cloned 
from a bone marrow biopsy-derived line obtained from a 
four-year old female with neuroblastoma, called SK-N-SH 
and first reported in 1973 (26). It has been demonstrated that 
VEGF produced from tumor cells is essential for the progres-
sion of experimental neuroblastoma and may function in both 
paracrine and autocrine manners to allow tumor expansion 
and growth in the SH-SY5Y neuroblastoma cell line (25). 
At present, the role of melatonin in the regulation of cancer 
cell growth, more particularly in estrogen-dependent tumors, 
is well established (9-11,14,16,17,27). Lissoni et al (28) were 
the first to suggest that melatonin could exert anti-angiogenic 
effects in cancer and they also demonstrated a decrease in the 
serum levels of VEGF in cancer patients treated with mela-
tonin. The effects of melatonin on angiogenesis have been 
studied in pancreatic, colon, breast, lung, hepatocellular and 
cervical cancer (23,29-32). In the present study, our objec-
tive was to demonstrate the usefulness of melatonin against 
the pro-angiogenic effects of either VEGF or the conditioned 
media from human neuroblastoma cells (SH-SY5Y).
The present study demonstrated that melatonin treatment 
has anti-angiogenic activity at different steps of the 
angiogenic process in SH-SY5Y cells. Melatonin inhibited 
the pro-angiogenic effects of SH-SY5Y cells and decreased 
the pro-angiogenic effects of the conditioned media from 
the SH-SY5Y cells stimulating proliferation, migration 
and tubular network formation by endothelial cells. After 
disruption of the vessel wall, endothelial cells must adhere 
to the extracellular matrix in the stromal space, migrate out 
from the original vascular structure, proliferate and organize 
into new vascular structures. Each of these processes was 
simulated in part by one of the in vitro assays used. Melatonin 
at a concentration of 1 mM had an inhibitory effect on cell 
proliferation of the neuroblastoma cell line. SH-SY5Y cells 
express melatonin MT1 receptor and different aspects related 
with their growth are modulated by this indolamine; thus, 
melatonin induces apoptosis (33), histone hyperacetylation (34) 
or anti-neuroinflammatory effects (35) in this neuroblastoma 
cell line. The effects of melatonin on cancer cells depend 
on different factors, such as its concentration, duration of 
exposure and the characteristics of the cells assessed. In 
the present study, only pharmacological concentrations of 
melatonin were effective. In previous studies (10-12,17,36), a 
strong inhibitory effect induced by nanomolar concentrations 
of melatonin on human breast cancer cells has been described. 
However, high concentrations of melatonin are necessary to 
obtain oncostatic effects in many other types of normal and 
cancer cells (31,33,37-39). Melatonin is a highly lipid-soluble 
indolamine which may easily cross the blood-brain barrier, 
and there is evidence that melatonin concentration in the 
cerebrospinal fluid is higher than in blood (40). Melatonin is 
also three orders of magnitude more concentrated in neoplastic 
and adipose tissue of the breast (41). These high concentrations 
of melatonin in some tissues may explain why high levels of 
melatonin are necessary to achieve oncostatic effects.
Since endothelial cell migration/invasion is essential for 
the formation of new blood vessels during neo-angiogenesis, 
we next studied the regulatory effects of melatonin on the 
conditioned media collected from the SH-SY5Y cells, which 
are angiogenically active and able to increase the migration of 
endothelial cells. Thus, the conditioned media from SH-SY5Y 
cells stimulated the migration of endothelial cells and this 
effect was significantly counteracted by the addition of either 
anti-VEGF or 1 mM of melatonin. These results suggest that 
VEGF produced by tumor cells could be responsible for 
inducing a proliferative response of endothelial cells.
Another important step during neo-angiogenesis is the 
formation of tubes by endothelial cells forming a complex 
network of vessels and capillaries (2,42,43). To study the effects 
of melatonin on this biological event we used an endothelial 
cell capillary-like tube formation assay. Endothelial cells 
plated on a basement membrane extract formed a massive 
network of tubes. Conditioned medium collected from the 
neuroblastoma cells was angiogenically active and stimulated 
tube formation. This effect was significantly counteracted by 
the addition of either the anti-VEGF antibody or melatonin, 
which suggests that melatonin-decreased capillary structure 
formation stimulated by the conditioned media from the 
SH-SY5Y cells, may occur through the inhibition of VEGF. 
Our results support the hypothesis that melatonin decreases 
the proliferation, migration and tube formation of endothelial 
cells by regulating the production of VEGF by neuroblastoma 
cells. We found that the same concentration of melatonin that 
inhibits the proliferation of SH-SY5Y cells also decreases the 
levels of VEGF in neuroblastoma cell-culture media. Previous 
studies have described a decrease in the production of VEGF 
protein induced by melatonin in human pancreatic carcinoma 
cells (PANC-1), human alveolar adenocarcinoma cells (A549) 
and human breast cancer cells (MCF-7) (29,31,32). With the 
aim of determining whether this inhibitory effect of melatonin 
on VEGF production was due to a downregulation of the 
VEGF mRNA expression in SH-SY5Y cells, we then incubated 
SH-SY5Y cells with different melatonin concentrations. 
The results obtained demonstrate that melatonin did in fact 
downregulate VEGF mRNA expression. SH-SY5Y cells were 
also exposed to cobalt chloride (CoCl2) to mimick hypoxia, 
a well-known inducer of VEGF mRNA expression, and the 
addition of 1 mM of melatonin significantly counteracted the 
stimulatory effect of CoCl2 on VEGF mRNA gene expression. 
It has been shown that the pharmacological concentrations 
of melatonin also suppress the VEGF mRNA expression 
induced by cobalt chloride in other tumor cells, such as human 
pancreatic carcinoma (PANC-1), human breast cancer (MCF-7) 
and human alveolar adenocarcinoma cells (A549) (29,31,32). In 
these tumor cells, melatonin also decreases hypoxia-inducible 
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factor (HIF)-1α protein levels, suggesting a role for transcription 
factor HIF-1α in the suppression of VEGF expression (29,30). 
In the present study, we developed a co-culture system 
of HuVECs and SH-SY5Y cells to investigate whether 
neuroblastoma cells affect the growth of the endothelial cells. 
We found that HuVECs exhibited increased cell proliferation 
when they were co-cultured with neuroblastoma cells and 
this process was prevented when melatonin was added to 
the culture medium. These results suggested that the local 
VEGF produced by tumor cells could be responsible for the 
proliferative response of endothelial cells. undoubtedly, the 
presence of neuroblastoma cells increased the protein levels 
of VEGF in the cell co-culture media and the addition of 
melatonin decreased the concentration levels of VEGF and 
counteracted the stimulatory effect induced by the presence of 
neuroblastoma cells. In addition, to demonstrate the paracrine 
effects of neuroblastoma-secreted VEGF on HuVEC growth, 
we studied whether VEGF within the conditioned medium 
collected from the neuroblastoma cell cultures was able to 
increase the proliferation of HuVECs. When the conditioned 
medium was added to the HuVECs in the culture, their growth 
was stimulated. The proliferative response of the HuVECs was 
abolished in the presence of an anti-VEGF antibody, indicating 
that VEGF produced by the neuroblastoma cells was the 
major factor that induces cellular proliferation in endothelial 
cells. When melatonin was added to the HuVEC cultures in 
the presence of the conditioned medium collected from the 
neuroblastoma cells, the stimulatory effect of the conditioned 
medium was also counteracted by this indolamine.
The present study, describes the anti-angiogenic effects of 
melatonin in relation to neuroblastoma. The anti-angiogenic 
effects of melatonin through its inhibitory effects on VEGF 
have also been described in human pancreatic carcinoma cells 
(PANC-1), human alveolar adenocarcinoma (A549), human 
colon cancer (HCT116), human breast cancer (MCF-7), 
cervical cancer cells (HeLa) and adenocarcinomic human 
alveolar basal epithelial cells (29-32). All these findings 
support a model in which neuroblastoma cells produce VEGF 
that functions in a paracrine manner to increase proliferation, 
invasion, migration and tube formation of endothelial cells. 
Melatonin may play a role in the paracrine interactions 
between neuroblastoma cells and proximal endothelial cells 
through the downregulation of the expression of VEGF in 
SH-SY5Y cells, thus decreasing the levels of VEGF around 
endothelial cells. Lower levels of VEGF could be important 
in decreasing endothelial cell proliferation, invasion, migra-
tion and tube formation. Collectively, our findings suggest that 
the anti-angiogenic effects of melatonin provide a promising 
therapeutic approach for the treatment of neuroblastoma.
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